Back to Top
World Gastroenterology Organisation
World Gastroenterology Organisation
WGO: Facebook WGO: Twitter

Irritable Bowel Syndrome (IBS)

Level: Meta-analyses, Systematic reviews, Practice guidelines: 47 Abstracts

Legend: : Key Development,  : Very Important,  : Important, [no star]: Special Mention


American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S; Amercian Gastroenterological Association., Gastroenterology. 2014 Nov;147(5):1146-8. doi: 10.1053/j.gastro.2014.09.001. Epub 2014 Sep 16. No abstract available. Erratum in: Gastroenterology. 2015 Feb;148(2):455. multiple investigator names added.
Comments: AGA recommendations


Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI.
Murray K(1), Wilkinson-Smith V(2), Hoad C(1), Costigan C(1), Cox E(1), Lam C(2), Marciani L(2), Gowland P(1), Spiller RC(2)., Am J Gastroenterol. 2014 Jan;109(1):110-9. doi: 10.1038/ajg.2013.386. Epub 2013 Nov 19.

Comments: MRI study showing that fructose but not inulin distends the small bowel with water (SBWC). Adding glucose to fructose reduces the effect of fructose on SBWC and breath hydrogen. Inulin distends the colon with gas more than fructose, but causes few symptoms in healthy volunteers.


Taste receptors of the gut: emerging roles in health and disease.
Depoortere I., Gut. 2014 Jan;63(1):179-90. doi: 10.1136/gutjnl-2013-305112. Epub 2013 Oct 16.

Comments: Chemosensory cells in the gut act in much the same way as the tongue, through the use of similar G-protein-coupled taste receptors. These receptors transmit signals that also the release of gut hormones and neurotransmitters, and play a role in the communication between the lumen, epithelium, smooth muscle cells, afferent nerve fibers and the brain. Targeting these receptors may represent a promising novel route for therapy.


Pharmacologic Management of Irritable Bowel Syndrome.
Rao VL, Cifu AS, Yang LW; American Gastroenterological Association., JAMA. 2015 Dec 22-29;314(24):2684-5. doi: 10.1001/jama.2015.16943. No abstract available.


Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis.
Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P., Am J Gastroenterol. 2014 Oct;109(10):1547-61; quiz 1546, 1562. doi: 10.1038/ajg.2014.202. Epub 2014 Jul 29. Review.
Comments: About treatment of IBS with probiotics


A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
Halmos EP(1), Power VA(2), Shepherd SJ(2), Gibson PR(3), Muir JG(3)., Gastroenterology. 2014 Jan;146(1):67-75.e5. doi: 10.1053/j.gastro.2013.09.046. Epub 2013 Sep 25.

Comments: In a controlled, cross-over study of patients with IBS, a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols effectively reduced functional gastrointestinal symptoms.


Therapeutic potential of fecal microbiota transplantation.
Smits LP(1), Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M., Gastroenterology. 2013 Nov;145(5):946-53. doi: 10.1053/j.gastro.2013.08.058. Epub 2013 Sep 7.

Comments: Review of best methods for performing fecal microbiota transplantation and summary of clinical observations that have implicated the intestinal microbiota in various diseases.


Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?
Hughes PA(1), Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D., Am J Gastroenterol. 2013 Jul;108(7):1066-74. doi: 10.1038/ajg.2013.120. Epub 2013 May 7.

Comments: Immunological alterations are increasingly reported in IBS patients.


No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates.
Biesiekierski JR(1), Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR., Gastroenterology. 2013 Aug;145(2):320-8.e1-3. doi: 10.1053/j.gastro.2013.04.051. Epub 2013 May 4.

Comments: A placebo-controlled, cross-over rechallenge study showing no effects of gluten in self-reported non-celiac gluten sensitivity.


Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis.
Videlock EJ, Cheng V, Cremonini F., Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3. doi:10.1016/j.cgh.2013.04.032. Epub 2013 May 2.

Comments: Metaanalysis documented that Linaclotide, a minimally absorbed, 14-amino acid peptide,improves bowel function and reduces abdominal pain and overall severity of IBS- with constipation.


Report from the multinational irritable bowel syndrome initiative 2012.
Pimentel M, Talley NJ, Quigley EM, Hani A, Sharara A, Mahachai V., Gastroenterology. 2013 Jun;144(7):e1-5. doi: 10.1053/j.gastro.2013.04.049. Epub2013 Apr 30.


An update on the use and investigation of probiotics in health and disease.
Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA., Gut. 2013 May;62(5):787-96. doi: 10.1136/gutjnl-2012-302504. Epub 2013 Mar 8.


Long-term success of GUT-directed group hypnosis for patients with refractoryirritable bowel syndrome: a randomized controlled trial.
Moser G, Trägner S, Gajowniczek EE, Mikulits A, Michalski M, Kazemi-Shirazi L,Kulnigg-Dabsch S, Führer M, Ponocny-Seliger E, Dejaco C, Miehsler W., Am J Gastroenterol. 2013 Apr;108(4):602-9. doi: 10.1038/ajg.2013.19. Epub 2013 Feb 19.

Comments: Gut-directed hypnotherapy improves IBS-related QOL for a long-time.


A controlled trial of gluten-free diet in patients with irritable bowelsyndrome-diarrhea: effects on bowel frequency and intestinal function.
Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O'Neill J, CarlsonP, Lamsam J, Janzow D, Eckert D, Burton D, Zinsmeister AR., Gastroenterology. 2013 May;144(5):903-911.e3. doi: 10.1053/j.gastro.2013.01.049. Epub 2013 Jan 25.

Comments: Gluten alters bowel barrier functions in patients with IBS-D, particularly in HLA-DQ2/8-positive patients.


Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis.
Sainsbury A, Sanders DS, Ford AC., Clin Gastroenterol Hepatol. 2013 Apr;11(4):359-65.e1. doi:10.1016/j.cgh.2012.11.033. Epub 2012 Dec 13.


Non-surgical interventions for the management of chronic pelvic pain.
Cheong YC(1), Smotra G, Williams AC., Cochrane Database Syst Rev. 2014 Mar 5;3:CD008797. doi:10.1002/14651858.CD008797.pub2.

Comments: Chronic pelvic pain is a common and debilitating condition with a multifactorial etiology, involving social, psychological and biological factors. Studies of moderate quality may support progestogen as an option.


Homeopathy for treatment of irritable bowel syndrome.
Peckham EJ(1), Nelson EA, Greenhalgh J, Cooper K, Roberts ER, Agrawal A., Cochrane Database Syst Rev. 2013 Nov 13;11:CD009710. doi:10.1002/14651858.CD009710.pub2.

Comments: No conclusions can be drawn from current studies on homeopathy in IBS.


Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock EJ(1), Cheng V, Cremonini F., Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi:10.1016/j.cgh.2013.04.032. Epub 2013 May 2.

Comments: Linaclotide, a minimally absorbed 14-amino acid peptide, improves bowel function and reduces abdominal pain in IBS with constipation.


Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS(1), Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G,Almenoff JS, Covington PS., Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.

Comments: Phase 2 study of the mixed µ-opioid receptor agonist/d-opioid receptor antagonist eluxadoline in IBS with diarrhoea sig improved abdominal pain and stool consistency.


Assessment of small bowel motility in patients with chronic intestinal pseudo-obstruction using cine-MRI.
Ohkubo H(1), Kessoku T, Fuyuki A, Iida H, Inamori M, Fujii T, Kawamura H, Hata Y,Manabe N, Chiba T, Kwee TC, Haruma K, Matsuhashi N, Nakajima A, Takahara T., Am J Gastroenterol. 2013 Jul;108(7):1130-9. doi: 10.1038/ajg.2013.57. Epub 2013 Mar 19.

Comments: Cine-MRI clearly detected contractility impairments in chronic intestinal pseudo-obstruction (CIPO) patients. Cine-MRI is noninvasive, radiation-free, and can directly evaluate the entire small bowel peristalsis.


Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: a meta-analysis.
Sainsbury A, Sanders DS, Ford AC., Clin Gastroenterol Hepatol. 2013 Apr;11(4):359-65.e1. doi:10.1016/j.cgh.2012.11.033. Epub 2012 Dec 13.


Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis.
Lovell RM, Ford AC., Am J Gastroenterol. 2012 Dec;107(12):1793-801; quiz 1802. doi:10.1038/ajg.2012.336. Epub 2012 Oct 2.


A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE,Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM., Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725.


Linaclotide for irritable bowel syndrome with constipation: a 26-week,randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, MacDougall JE, JiaXD, Shao JZ, Fitch DA, Baird MJ, Schneier HA, Johnston JM., Am J Gastroenterol. 2012 Nov;107(11):1702-12.


Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity.
Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, Brusca I,Florena AM, Ambrosiano G, Seidita A, Pirrone G, Rini GB., Am J Gastroenterol. 2012 Dec;107(12):1898-906; quiz 1907. doi:10.1038/ajg.2012.236. Epub 2012 Jul 24.


Intestinal microbiota in functional bowel disorders: a Rome foundation report.
Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee., Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22.


Effect of gender on prevalence of irritable bowel syndrome in the community:systematic review and meta-analysis.
Lovell RM, Ford AC., Am J Gastroenterol. 2012 Jul;107(7):991-1000. doi: 10.1038/ajg.2012.131. Epub2012 May 22.


Acupuncture for treatment of irritable bowel syndrome.
Manheimer E, Cheng K, Wieland LS, Min LS, Shen X, Berman BM, Lao L., Cochrane Database Syst Rev. 2012 May 16;5:CD005111. doi:10.1002/14651858.CD005111.pub3.


Acupuncture for irritable bowel syndrome: systematic review and meta-analysis.
Manheimer E, Wieland LS, Cheng K, Li SM, Shen X, Berman BM, Lao L., Am J Gastroenterol. 2012 Jun;107(6):835-47; quiz 848. doi: 10.1038/ajg.2012.66. Epub 2012 Apr 10.


Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis.
Lovell RM, Ford AC., Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi:10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.


The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.
Menees SB, Maneerattannaporn M, Kim HM, Chey WD., Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.


Effects of gut-directed hypnotherapy on IBS in different clinicals ettings-results from two randomized, controlled trials.
Lindfors P, Unge P, Arvidsson P, Nyhlin H, Björnsson E, Abrahamsson H, Simrén M., Am J Gastroenterol. 2012 Feb;107(2):276-85. doi: 10.1038/ajg.2011.340. Epub 2011 Oct 4.


Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.
Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW., Cochrane Database Syst Rev. 2011 Aug 10;(8):CD003460.


Role of clock genes in gastrointestinal motility.
Hoogerwerf WA., Am J Physiol Gastrointest Liver Physiol. 2010 Sep;299(3):G549-55. Epub 2010 Jun 17.


The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review.
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM., Gut. 2010 Mar;59(3):325-32. Epub 2008 Dec 17.


Review article: new receptor targets for medical therapy in irritable bowel syndrome.
Camilleri M, Aliment Pharmacol Ther. 2010 Jan;31(1):35-46


Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
Halpin SJ, Ford AC., Am J Gastroenterol. 2012 Oct;107(10):1474-82. doi: 10.1038/ajg.2012.260. Epub 2012 Aug 28.


A prospective randomized trial of mosapride vs. placebo inconstipation-predominant irritable bowel syndrome.
Mansour NM, Ghaith O, El-Halabi M, Sharara AI., Am J Gastroenterol. 2012 May;107(5):792-3. doi: 10.1038/ajg.2012.26.


Antidepressants for the treatment of abdominal pain-related functionalgastrointestinal disorders in children and adolescents.
Kaminski A, Kamper A, Thaler K, Chapman A, Gartlehner G., Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008013.


Quantitative meta-analysis identifies brain regions activated during rectaldistension in irritable bowel syndrome.
Tillisch K, Mayer EA, Labus JS., Gastroenterology. 2011 Jan;140(1):91-100. Epub 2010 Aug 7.


Systematic review: self-management support interventions for irritable bowelsyndrome.
Dorn SD., Aliment Pharmacol Ther. 2010 Aug;32(4):513-21. Epub 2010 May 22.


Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?
Adeyemo MA, Spiegel BM, Chang L., Aliment Pharmacol Ther. 2010 Sep;32(6):738-55. doi:10.1111/j.1365-2036.2010.04409.x. Epub 2010 Jul 22.


Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome.
Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX., J Gastroenterol. 2010 Sep 17. [Epub ahead of print]


Systematic Review and Meta-Analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia.
Ford AC, Marwaha A, Lim A, Moayyedi P, Clin Gastroenterol Hepatol. 2009 Jul 23;


Do Corticotropin Releasing Factor-1 Receptors Influence Colonic Transit and Bowel Function in Females with Irritable Bowel Syndrome?
Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR, Am J Physiol Gastrointest Liver Physiol. 2009 Apr 2;


A Very Low-Carbohydrate Diet Improves Symptoms and Quality of Life in Diarrhea-Predominant Irritable Bowel Syndrome.
Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS Jr, Drossman DA, Clin Gastroenterol Hepatol. 2009 Mar 10;


The Clinical Course of Postinfectious Irritable Bowel Syndrome: A Five-year Follow-up Study.
Jung IS, Kim HS, Park H, Lee SI, J Clin Gastroenterol. 2009 Mar 3;